BIOMAT Database Logo BIOMAT Database Logo

Plasma levels of leukotriene C4, B4, slow reacting substance of anaphylaxis in chronological phases of cerebrovascular disease. 1988

K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Second Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

In this study we report and compare plasma leukotriene (LT) levels in seventeen (17) patients with cerebral infarction, five (5) patients with cerebral hemorrhage and twelve (12) age-matched healthy volunteers. Plasma samples were collected at intervals of 1-7 days, 8-14 days, 15-30 days and 31 days- after cerebrovascular accident. Plasma immunoreactive LTC4, LTB4 and SRS-A (Slow Reacting Substance of Anaphylaxis or total peptido-LT's) levels were measured for each sample. Immunoreactive LTC4 (and SRS-A) levels were elevated in patients with cerebral infarction whilst LTB4 levels were raised in the patients with cerebral hemorrhage. In particular, cerebral infarcted patients exhibited significantly elevated levels in phases 1-7 days and after 15 days when compared with the age-matched healthy volunteers. In patients with cerebral hemorrhage, significant increases in LTB4 were measured in days 1-7 only. These results suggest a clinical relationship between the plasma levels of LT's and cerebrovascular disease.

UI MeSH Term Description Entries
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002543 Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA. Brain Hemorrhage, Cerebral,Cerebral Parenchymal Hemorrhage,Hemorrhage, Cerebral,Intracerebral Hemorrhage,Hemorrhage, Cerebrum,Brain Hemorrhages, Cerebral,Cerebral Brain Hemorrhage,Cerebral Brain Hemorrhages,Cerebral Hemorrhages,Cerebral Parenchymal Hemorrhages,Cerebrum Hemorrhage,Cerebrum Hemorrhages,Hemorrhage, Cerebral Brain,Hemorrhage, Cerebral Parenchymal,Hemorrhage, Intracerebral,Hemorrhages, Cerebral,Hemorrhages, Cerebral Brain,Hemorrhages, Cerebral Parenchymal,Hemorrhages, Cerebrum,Hemorrhages, Intracerebral,Intracerebral Hemorrhages,Parenchymal Hemorrhage, Cerebral,Parenchymal Hemorrhages, Cerebral
D002544 Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction). Anterior Choroidal Artery Infarction,Cerebral Infarct,Infarction, Cerebral,Posterior Choroidal Artery Infarction,Subcortical Infarction,Cerebral Infarction, Left Hemisphere,Cerebral Infarction, Right Hemisphere,Cerebral, Left Hemisphere, Infarction,Cerebral, Right Hemisphere, Infarction,Infarction, Cerebral, Left Hemisphere,Infarction, Cerebral, Right Hemisphere,Infarction, Left Hemisphere, Cerebral,Infarction, Right Hemisphere, Cerebral,Left Hemisphere, Cerebral Infarction,Left Hemisphere, Infarction, Cerebral,Right Hemisphere, Cerebral Infarction,Right Hemisphere, Infarction, Cerebral,Cerebral Infarctions,Cerebral Infarcts,Infarct, Cerebral,Infarction, Subcortical,Infarctions, Cerebral,Infarctions, Subcortical,Infarcts, Cerebral,Subcortical Infarctions
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
The Paul Kallós Memorial Lecture. From slow-reacting substance of anaphylaxis to leukotriene C4 synthase.
January 1995, International archives of allergy and immunology,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Release of slow-reacting substance of anaphylaxis and leukotriene C4-like immunoreactivity from guinea pig colonic tissue.
June 1983, Prostaglandins,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Slow reacting substance of anaphylaxis.
January 1969, Advances in immunology,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Slow-reacting substance of anaphylaxis.
May 1978, Annals of the Royal College of Surgeons of England,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
From slow reacting substance of anaphylaxis (SRS-A) to leukotriene D4 (LTD4).
January 1980, International journal of immunopharmacology,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Slow-reacting substance of anaphylaxis--leukotrienes.
June 1980, Lancet (London, England),
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Tissue inactivation of slow reacting substance of anaphylaxis.
January 1976, Immunology,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Selective inhibitor of slow reacting substance of anaphylaxis.
October 1973, Nature: New biology,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
Slow-reacting substance of anaphylaxis: purification and characterisation.
March 1978, FEBS letters,
K Katsura, and H Minamisawa, and Y Katayama, and J Shimizu, and T Goto, and K Urushiyama, and A Terashi, and Y Kanda, and Y Yoshino
"SRS-A" The slow reacting substance of anaphylaxis.
April 1963, Biochemical pharmacology,
Copied contents to your clipboard!